Avenue Therapeutics, Inc. announced the termination of its license agreement with AnnJi Pharmaceutical on April 24, 2025, following disputes, leading to a transfer of rights related to the AJ201 product. Avenue will receive up to $20 million over time and a 1.75% royalty on AJ201 sales, while repurchasing shares from AnnJi for $1.00.